Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026)

Amarin Corp Plcuk (AMRN) posted quarterly Total Non-Current Liabilities of $185.2 million for Q1 2026, up 8.74% YoY from $170.3 million in Q1 2025, and down 7.63% sequentially from $200.5 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $185.2 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 8.74% year-over-year to $185.2 million; the TTM figure through Mar 2026 stood at $185.2 million (up 8.74% YoY), while the FY2025 annual figure was $200.5 million, up 6.86% from the prior year.
  • Total Non-Current Liabilities declined to $185.2 million in Q1 2026, from $200.5 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for AMRN reached as high as $385.6 million in Q2 2022 and fell as low as $170.3 million in Q1 2025.
  • The 5-year median for Total Non-Current Liabilities is $238.6 million (2024), against an average of $247.8 million.
  • Annual changes were most pronounced in 2024 — Total Non-Current Liabilities slumped 30.63% — and 2026, when it gained 8.74%.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $282.6 million in 2022, then retreated by 4.29% to $270.5 million in 2023, then tumbled by 30.63% to $187.7 million in 2024, then climbed by 6.86% to $200.5 million in 2025, then dropped by 7.63% to $185.2 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $185.2 million, $200.5 million, and $189.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 48.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 119.22 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 109.01 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -34.06 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 75.17 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 31.56 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 113.51 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 100.00 Mn
10 Amarin Corp Plcuk 5.17 Bn 5.00 Bn 17.77 Mn 185.23 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 185.23 Mn
Dec 31, 2025 200.54 Mn
Sep 30, 2025 188.96 Mn
Jun 30, 2025 193.28 Mn
Mar 31, 2025 170.35 Mn
Dec 31, 2024 187.67 Mn
Sep 30, 2024 209.77 Mn
Jun 30, 2024 238.64 Mn
Mar 31, 2024 234.88 Mn
Dec 31, 2023 270.52 Mn
Sep 30, 2023 278.61 Mn
Jun 30, 2023 283.74 Mn
Mar 31, 2023 266.79 Mn
Dec 31, 2022 282.64 Mn
Sep 30, 2022 310.78 Mn
Jun 30, 2022 385.56 Mn
Mar 31, 2022 325.11 Mn
Dec 31, 2021 393.32 Mn
Sep 30, 2021 387.96 Mn
Jun 30, 2021 394.14 Mn